Clinical Trial Update: Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment [Phase 3]

View source ↗

Summary

Clinical trial update indicates AMX0035 is in a Phase III study for amyotrophic lateral sclerosis that is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• AMX0035 (sodium phenylbutyrate and tauroursodeoxycholic acid)

Snippet

Sponsor: Amylyx Pharmaceuticals Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING